A multicenter, open-label trials to evaluate the long-term safety and tolerability of a new balsalazide disodium tablet formulation in patients with ulcerative colitis
Phase of Trial: Phase III
Latest Information Update: 09 Mar 2018
At a glance
- Drugs Balsalazide (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions
- Sponsors Salix Pharmaceuticals
- 11 Oct 2013 Results will be presented at the American College of Gastroenterology (ACG) 2013 Annual Scientific Meeting according to a Salix Pharmaceuticals media release.
- 29 Dec 2009 Actual initiation date (Oct 2006) added as reported by ClinicalTrials.gov.
- 29 Dec 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.